View all IQVIA events
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Our Latest Whitepapers
Get the latest insights on our life sciences, healthcare, and medical technology solutions in Asia Pacific.
Learn MoreBlogs, Case Studies & Podcasts
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
Discover Insights
IQVIA APAC Insight
"A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the Asia Pacific healthcare market.
Read The Latest IssueCareer Opportunities
Improving human health requires innovative thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
Search JobsThe drug development landscape in Asia Pacific is accelerating more than ever before. Emerging biotech companies now face multiple hurdles in the clinical development process – from learning to prioritize the right target indication, effectively designing robust clinical study program with integration of right biomarkers ultimately seeking compressed development timelines.
With increasing trial complexity and decreasing success rate for oncology assets in the clinical productivity index, it is critical for small sponsors to identify the right target disease indication and consider the appropriate biomarker strategies right from the start of your early clinical development plan.
Why you should attend:- Learn how Indication Prioritization analysis can increase the return of investment of your oncology assets
- Gain insights into how IQVIA Biotech can support your oncology early assets through our CDP oncology program
- Learn how to integrate biomarker strategies in the framework of clinical trial and laboratory operations
Join this webinar to learn how JAPAC IQVIA Biotech leverages data and expertise to support your strategic drug development for early oncology assets to ensure your success.
Key speakers
Christopher Hart
Senior Director, Drug Development Lead, Planning and Design Operations
Eric Groves
Vice President, Strategic Drug Development, Design and Delivery Innovation
Bradley Smith
Vice President, Strategic Drug Development, Translational Medicine
Megan McCausland
Scientific Advisor, Q2 Solutions